Detail Study on Medical Carts Market is Projected to Grow Magnificent CAGR till 2023

 Medical Carts Market Analysis  

The medical carts market was worth USD 1,100 million in 2017 and is likely to grow at a 12.1% CAGR between 2017- 2023, according to the recent report by Market Research Future (MRFR). A medical cart or a medical trolley, simply put, is a wheeled cabinet having trays and drawers which are used in different therapeutic, surgical, and medical modalities. Medical carts are extensively used across clinical settings and hospitals for keeping drugs, medical devices, equipment, and tools for specified treatments. Wall-mounted workstations, medical computing carts, mobile computing carts, medication carts, & others are the different types of medical carts. It is available in different materials such as plastic, metal, and others. Owing to its various benefits and alluring features, medical carts are widely used in hospitals and clinics, ambulatory surgical centre, and others.  

Get a FREE Sample (Including COVID19 Impact Analysis, Full TOC, Tables and Figures) of Medical Carts Market @ https://www.marketresearchfuture.com/sample_request/7436 

Various factors are adding to the global medical carts market growth. These factors, as per the latest MRFR report, comprise increasing use of medical carts at home, easy availability of advanced medical cart through e-commerce & retail stores, technological advances in medical devices, and rising cases of musculoskeletal injury.  

On the contrary, the high price of advanced medical carts, especially in developing countries, may limit the medical carts market growth over the forecast period. 

Medical Carts Market Segmentation 

The MRFR report provides an inclusive segmental analysis of the global medical carts market report based on end users, material type, product type, and type.  

By product type, the medical carts market is segmented into wall-mounted workstations, medical computing carts, mobile computing carts, medication carts, & others. Of these, mobile computing carts will lead the market over the forecast period.  

By type, the medical carts market is segmented into emergency cart, computer medical cart, anaesthesia cart, procedure cart, and others. Of these, emergency medical carts will dominate the market over the forecast period.  

By material type, the medical carts market is segmented into plastic type, metal type, and others. Of these, the metal segment will have a major share over the forecast period.  

By end user, the medical carts market is segmented into ambulatory surgical centre, hospitals & clinics, and others. Among these, hospitals and clinics will have lions share over the forecast period.  

Medical Carts Market Regional Analysis 

Based on the region, the medical carts market report covers the recent trends and growth opportunities across the Americas, Europe, the Asia Pacific (APAC), and the Middle East and Africa (MEA). Of these, the Americas will have the lions share in the market over the forecast period. Increased usage of medical carts for different applications, rising awareness among physicians and patients, and improving research infrastructure are adding market growth in the region.  

The medical carts market in Europe is predicted to hold the second-largest share over the forecast period. Increasing acceptance in developing countries, coupled with growing cases of chronic diseases, is adding market growth in the region.  

The medical carts market in the APAC region is predicted to grow at a high CAGR over the forecast period. Rising patient safety at the community level and hospitals are adding market growth in the region.  

The medical carts market in the MEA is predicted to have the smallest share over the forecast period for the scarcity of well-trained healthcare professionals and low per capita income. 

Medical Carts Market Key Players 

Key players profiled in the global medical carts market report include Ergotron Inc (US), Waterloo Healthcare (US), Jaco Inc (US), Capsa Healthcare (US), The Bergmann Group (US), Midmark Corporation (US), Omnicell Inc. (US), Chang Gung Medical Technology Co. (Taiwan), AFC Industries (US), Harloff Manufacturing Co. (US), Advantech Co. (Taiwan) Ltd, and ITD GmbH (Germany). Key players have adopted strategies such as acquisitions, new product launch, strategic alliance, and mergers to stay ahead in the competition. 

Browse Complete Report Details @ https://www.marketresearchfuture.com/reports/medical-carts-market-7436 

 

Advanced Wound Therapy Devices Market Poised to Witness a Significant Growth by 2023

 

Overview:

The global advanced wound therapy devices market is anticipated to touch a value of USD 2,804.53 million by 2023, asserts Market Research Future (MRFR). The market can showcase 6.70% CAGR from 2018 to 2023 (forecast period).

Increasing incidence of diabetes is the primary driver of the market. Patients with diabetes have a slower healing rate and poor blood circulation which can negatively affect the immunity system. According to the Centers for Disease Control & Prevention (CDC), nearly 30.3 million in the U.S. suffer from diabetes. The advanced wound therapy devices market can expand by capitalizing on this trend and offering precise solutions.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/7421

The growing numbers of the geriatric populace will be highly beneficial to the market. This is buttressed by the estimation by the World Health Organization (WHO) which pegs the elderly populace at 1.2 billion by 2025. Furthermore, development of novel products and rapid approval by regulatory bodies is projected to propel the advanced wound therapy devices market. For instance, ConvaTec got approval for its negative pressure wound therapy (NPWT) system by the U.S. FDA in 2018. The hydrofiber gels in the system lock the exudates and bacteria and offer a separate channel for the them to flow away from the wounded region.

Segmentation Analysis:

The advanced wound therapy devices market is segmented by type and end-user.

By type, negative pressure wound therapy systems accounted for 42.9% share in 2017, followed by pressure relief devices (28.2%), hyperbaric oxygen equipment (15.2%), electric stimulation devices (7.9%), and others (5.8%). Negative pressure wound therapy systems can attain revenue close to USD 1,217.41 million by 2023 at 6.91% CAGR over the forecast period. But pressure relief devices are projected to experience the highest CAGR of 7.03% during the assessment period to accrue close to USD 805.35 million by 2023.

Among end-users, hospitals & clinics accounted for 73.7% share in 2017, followed by home care settings (14.5%), and others (11.8%). Hospitals & clinics can register close to 6.95% CAGR during the forecast period to generate close to USD 2,095.66 million by 2023. On the other hand, the home care settings segment is expected to exhibit 6.78% CAGR to touch a size of USD 408.50 million by the end of the forecast period.

Regional Analysis:

Region-wise, the advanced wound therapy devices market is segmented into Europe, Asia Pacific (APAC), Americas, and the Middle East & Africa (MEA).

The Americas are anticipated to reign as the leading region of the market owing to a mix of attractive reimbursement schemes, numerous treatment options, and prevalence of diabetes and chronic wounds. The region can accumulate close to USD 993.07 million by 2023 at 6.11% CAGR over the forecast period.

The European region is touted to register a notable growth rate owing to awareness of chronic wounds, rise in government initiatives, and awareness among healthcare providers. Presence of reputed companies such as Lohmann & Rauscher and technological advances of products can drive the regional advanced wound therapy devices market growth. The region can accrue close to USD 924.85 million by 2023 at 7.02% CAGR over the forecast period.

The APAC region is expected to be extremely lucrative for the advanced wound therapy devices market. This can be credited to high number of burn injury cases and awareness of NPWT devices. It can attain a size of USD 676.27 million by 2023 at 7.16% CAGR over the assessment period.

Competitive Analysis:

Notable player names in the advanced wound therapy devices market are Cardinal Health (U.S.), ConvaTec Inc. (U.K.), Smith & Nephew plc (U.K.), Triage Meditech Pvt. Ltd. (India), Medela AG (Switzerland), Sechrist (U.S.), Mölnlycke Health Care AB (Sweden), B. Braun Melsungen AG (Germany), DeRoyal Industries, Inc. (U.S.), Lohmann & Rauscher GmbH & Co. KG (Germany), Perry Baromedical (U.S.), and KCI Licensing, Inc. (U.S.).

Browse Complete Report Details @ https://www.marketresearchfuture.com/reports/advanced-wound-therapy-devices-market-7421

Cell Surface Markers Market – Product Development is the best strategy for market position; Forecast till 2023

 

Market Highlights

The global cell surface markers market is anticipated to hold a market value of USD 498 million in the year 2017 and is expected to grow at a CAGR of 8.4% during the forecast period. Cell surface markers or cell surface antigen work as monograms for identification and classification of cells. The proteins that are expressed on the cell surfaces often conveniently work as markers for specific types of cells.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/7410 

Increasing expenditure in the advancement of healthcare technology, advancement in technology, acquisitions by companies and outlook for reduction of costs associated with disease diagnosis are expected to drive the growth in the market over the forecast period. For instance, in April 2014, Beckman Coulter, acquired Xitogen Technologies, a cytometer manufacturer. This acquisition helped Beckman Coulter to broaden its product offerings and enabled business expansion in Asia.  However, complex products and expensive instruments & reagents can restrain the market growth over the assessment period.

Regional Analysis

Geographically, the Americas is expected to dominate the global market owing to the significant amount of research and development activities and well-developed healthcare infrastructure. According to the Organization for Economic Co-operation and Development(OECD), In 2016 united states has spent USD 464,324 million on research and development activities which is 2.7% of total GDP.  Europe is expected to hold the second largest position in the global market owing to the well-developed healthcare infrastructure. Asia-Pacific is expected to be the fastest growing market owing to the growing demand for user friendly targeted therapies. Moreover, the Middle East and Africa region is expected to account for the least market share in the global market.

Segmentation

The global cell surface markers market has been segmented into product, source, cell type and application.

The market, on the basis of product, has been segmented into antibody and PCR array.

The global market, on the basis of source, has been segmented into mice, rat and others.

The global market, on the basis of cell type, has been segmented into T cells, B cells and NK cells. T cells are expected to hold the largest market share owing to high usage of them in research and diagnostics. NK cells are expected to grow at the fastest CAGR owing to increasing application of these types of cell.

The global cell surface markers market, by application, has been segmented into research, clinical and others. Research segment has been further divided into stem cell and immunology. Clinical segment is further divided into oncology and hematology.

Key Players

Some of the prominent players in the global cell surface markers market are Bio-Rad Laboratories, Inc., Abbott, Siemens Healthcare Private Limited, Beckman Coulter, Inc. , F. Hoffmann-La Roche Ltd, NIHON KOHDEN CORPORATION, Thermo Fisher Scientific, BD, Abcam plc., QIAGEN, Danaher, GenScript, Merk KGaA, BioLegend, Inc., Cell Signaling Technology, Inc., Bio-Techne and Others.

Browse Complete Report Details @ https://www.marketresearchfuture.com/reports/cell-surface-markers-market-7410

 

Hemangioblastoma Market to Perceive Momentous Accruals with a hefty CAGR By 2023

 The global hemangioblastoma market is expected to grow at the rate of 6.1% during the forecast period (2018–2023)

Hemangioblastoma is a type of brain tumor, it is rare and slow growing disease. Uncontrolled growth occurs in the cell linings of blood vessels and it leads to a tumor. The disease-causing factor is unknown, but it is more likely to affect people with von Hippel-Lindau disease history or it can be sporadically. The growing awareness about cancer, increasing number of tumor surgeries, growing demand for advanced therapies and increasing healthcare expenditure are expected to drive the growth of the market. According to National Center for Biotechnology Information, US National Library of Medicine, 80% cases of hemangioblastoma are sporadic, whereas 20 to 25% develop in the context of Von Hippel–Lindau disease and it accounts for 7 to 10% of total brain tumor cases.

The rising cost of tumor treatment and scarcity of experts may hamper the growth of the market during the assessment period.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6404 

Regional Analysis

The market in the Americas is expected to dominate the global hemangioblastoma market during the forecast period owing to the increasing prevalence of cancer along with the increasing healthcare expenditure, and well-established healthcare sector in the region. According to the American Cancer Society, there will be an estimated 1,735,350 new cancer cases diagnosed and 609,640 cancer deaths in the United States. The European market is expected to be the second-largest due to government funding and support of the healthcare sector, and technological advancement in the region. Germany is the most affected country in the region and it has the highest number of cancer patients. Moreover, the market in Asia-Pacific is anticipated to be the fastest-growing during the forecast period owing to technological development, an increasing number of chronic diseases, and favorable government initiatives for healthcare facilities. Asia-Pacific region has a large number of patients and it can provide opportunities for the major players in the market. The market in the Middle East & Africa is likely to account for the smallest share of the global hemangioblastoma market.

Segmentation

The global hemangioblastoma market has been segmented on the basis of tumor site, diagnosis, and treatment.

On the basis of the tumor site, the market has been classified as brain tumor, spinal cord tumor, and retinal tumor. A brain tumor is most common in all the three segments. The diagnosis segment has been classified as CT scan, MRI scan, and angiogram. According to the stage of cancer, experts can ask for multiple diagnostic tests.

The market, by treatment, has been segmented into surgery, chemotherapy, radiotherapy, corticosteroids, and anticonvulsants. Radiotherapy segment has been classified into conformal radiotherapy, intensity modulated radiotherapy (IMRT), stereotactic radiotherapy and radiosurgery. Corticosteroid segment has been further divided into hydrocortisone, dexamethasone, methylprednisolone, and prednisolone. Anticonvulsants segment has been further divided into carbamazepine, lamotrigine, levetiracetam, phenytoin, and sodium valproate.

Key Players

Some of the key players in the global hemangioblastoma market are Eli Lilly and Company, Bedford Laboratories, Astellas US Holding, Inc., DNAtrix, Inc., Advantagene, Inc., Burzynski Research Institute, Inc., Direct Therapeutics, Inc., Cellectar Biosciences, Inc., and others.

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/hemangioblastoma-market-6404 

Dental Practice Management Software Market Poised to Witness a Significant Growth by 2023

 Market Research Future (MRFR)’s study projects healthy growth for the global dental practice management software market in the forthcoming years.  The latest developments in oral healthcare technologies have paved the way for the adoption of software all across the world. Additionally, the increasing awareness about oral healthcare coupled with rising dental healthcare expenditure is expected to favor the expansion of the market over the next couple of years.

The exponential geriatric population has opened new avenues of growth opportunities for service providers in the oral healthcare industry. According to data published by World Population Prospects: the 2017 Revision, the population of older people, over 60 years, is expected to get doubled by 2050. It is anticipated to augment the oral healthcare industry. This, in turn, is prognosticated to accelerate the adoption of dental practice management software in the industry.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/6507

The growth trajectory of the market is guided by the rising technological advancements in the dental healthcare industry and its large-scale adoption. The need for better technology for enhanced efficiency has intensified in the dental healthcare industry. The large-scale prevalence of dental disorders owing to the changing lifestyle and food habits is another major factor responsible for complementing the growth of the global market. It is likely to accelerate the revenue creation for the market participants in the foreseeable future.

The market scenario looks attractive at present and is forecasted to remain highly lucrative in the coming years. Furthermore, investments are likely to flow towards the global dental practice management software market over the next couple of years. Nevertheless, lack of skilled personnel remains an impediment to the market proliferation.

Companies Covered

Some of the global dental practice management software market companies are Curve Dental, Practice Web, Henry Schein, NextGen Healthcare Information Systems, LLC., Carestream Dental, DentiMax, Patterson Dental, Allscripts Healthcare Solutions, and Dovetail Dental Software.

Report Overview

This MRFR report presents a comprehensive analysis of the key market trends and an outlook for product segments and major regions highlighting the growth trajectories during the assessment period. It reveals that dental practice management software finds application in invoicing/billing, charting, patient management, insurance management, and others. A detailed analysis is also included based on on-premise, web-based, and cloud-based deployment mode. The regional analysis of the market spans across North America, Europe, Asia Pacific, and the Rest of the World.

Report Coverage

Historical market trends, forecast, key player’s market share analysis, market dynamics, and market factor analysis which covers supply chain and Porter’s five forces analysis of the market. The report also encompasses market value by region as well as by segmentation, and country-level analysis for each market segment.

Research Methodology

MRFR leverages its industry expertise for delivering actionable insights into the markets. An in-depth study of the market elements influencing the forecast is performed for drawing insightful conclusions. The information presented in our reports are backed by data sourced through extensive primary and secondary research. Top-down and bottom-up approaches are employed for authenticating the accuracy of the market size and revenue estimation. A multi-layer verification process further affirms the credibility of the quantitative and qualitative data available in our reports.

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/dental-practice-management-software-market-6507

Costochondritis Market to Witness an Outstanding Growth by 2023

 Market Scenario

Costochondritis is an inflammatory condition of the cartilage which connects a rib to the sternum. It is sometimes called chest wall pain, costosternal chondrodynia, or costosternal syndrome. The pain caused by costochondritis might be similar to that of a heart attack. Costochondritis is a common cause of chest pain in adolescents and children. It is estimated that the global costochondritis treatment market is expected to register an increasing CAGR during the forecast period from 2018 to 2023.

The factors causing costochondritis can be injury in chest, physical strain, osteoarthritis, arthritis, ankylosing spondylitis, and tumors (cancerous or noncancerous).  Also, costochondritis may be caused by bacterial, viral, and fungal infections. According to the Centers for Disease Control and Prevention, August 2018, it has been estimated that 22.7% of the US adults had some form of rheumatoid arthritis from 2013 to 2015. The growing percentage of arthritis patients would support the costochondritis market positively.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/6500

However, factors such as the high cost of surgical procedures, expensive treatments, and side effects related to treatments are expected to restrict the market growth during the forecast period.

Segmentation

The global costochondritis market is segmented on the basis of diagnosis, treatment, and end-user. The costochondritis market, by diagnosis, is categorized into various tests. The test is sub-segmented into echocardiogram, electrocardiogram, stress tests, cardiac catheterization, chest X-ray, cardiac MRI, and CT scan. On the basis of treatment, the market is segmented into medications, therapy, and surgery.

The medications treatment is further sub-segmented into nonsteroidal anti-inflammatory drugs, narcotics, antidepressants, and anti-seizure drugs. Therapy is sub-segmented into stretching exercises and nerve stimulation. On the basis of end-user, the market is segmented into hospitals and clinics, ambulatory surgical centers, diagnostic centers, research centers, and others.

On the basis of region, the global costochondritis market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas is sub-segmented into North America and South America. The North American region is further segmented into the US and Canada. The European region is divided into two, namely, Western Europe and Eastern Europe. Western Europe is further classified into Germany, Italy, France, the UK, Spain, and the rest of Western Europe. The Asia-Pacific region is sub-segmented into Japan, China, India, Australia, the Republic of Korea, and the rest of Asia-Pacific. The Middle Eastern and African region is sub-segmented into the UAE, Saudi Arabia, Oman, Kuwait, Qatar, and the rest of the Middle East and Africa.

Key players

Some of the key players in the global costochondritis market are KemPharm, GlaxoSmithKline plc, Biovail Corporation, Aurobindo Pharma, Pfizer Inc., Recro Pharma Inc., LUPIN, Bausch Health Companies Inc., Avenue Therapeutics, and others.

Regional Market Summary

It is estimated that North America dominated the global costochondritis market owing to the increased cardiac diseases, increasing prevalence of syphilis, innovations in clinical practice, heart research, and access to heart treatments in this region. According to the Centers for Disease Control and Prevention (CDC), September 2017, the total syphilis cases reported to CDC increased by 17.8% during 2015 to 2016. The increase in the cases of syphilis supports the market growth in this region.

Europe stood the second largest in the costochondritis market owing to increasing hypertension and heart attack cases. According to the Public Health England in January 2017,

high blood pressure is the third highest risk factor for disease in the UK. It affected one in four adults and around 12.5 million people in 2015 in England. This number is expected to increase during the forecast period.  Such a high incidence of high blood pressure supports the growth of costochondritis in this region.

Asia-Pacific was estimated to be the fastest growing region for the global costochondritis market in 2017. The market is expected to witness growth owing to the rising prevalence of heart problems, car accidents, and changing lifestyle.

The Middle East and Africa holds the least share in the global costochondritis market due to the presence of low health expenditure, low awareness of innovative technology, and economically diverse countries. However, the market is expected to witness growth due to increasing cardiac care programs and an increase in investments in research and development in the Middle East.

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/costochondritis-market-6500

Global Blood Group Typing Market to Significant Growth Foreseen by 2023

 Market Scenario

Global blood group typing market size is expected to grow significantly over the forecast period. It is projected to grow at a CAGR of 10.2% over the assessment period. Blood group typing is a method of determining the type of blood group of an individual.  Blood group typing is a mandatory requirement before blood transfusion to examine the compatibility between the donor and recipient blood group. Additionally, blood typing is of significant importance in pregnant women in cases where the father of the baby has RhD positive blood group and the mother has RhD negative blood group. The global blood group typing has witnessed significant growth owing to the technological advancements in blood group detections methods. Technological advancements such as quantum dots (QDs) and magnetic beads in assays improve identification and thus enhance the clinical safety of the blood transfusion.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/6410

The factors such as growing demand for blood products need for blood grouping during prenatal testing, increasing number of road incidents, growing number of road accidents and trauma cases which requires a blood transfusion, the rise in blood donations, and growing usage of blood typing in the forensic sciences. According to The American National Red Cross, about 21 million blood components are transfused each year in the US. Following the same source, each year, an estimated 6.8 million people in the US donate blood.

However, the stringent regulatory requirements for blood transfusion may hinder the growth of the global blood group typing market.

Segmentation

The global blood group typing market has been segmented into technique, test type, product and service, and end user.

The market, by technique, has been segmented into PCR-based and microarray techniques, assay-based techniques, massively parallel sequencing, and others.

The market, by test type, has been segmented into antibody screening, HLA typing, ABO blood tests, cross-matching tests, and antigen typing.

The global market, on the basis of product and service, has been segmented into consumables, instruments, and services. The consumables segment has been segmented into antisera reagents, red blood cells reagents, anti-human globulin reagents, and blood bank saline.

On the basis of end user, the market has been segmented into hospitals, blood banks, clinical laboratories, and others.

The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The blood group typing market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European blood group typing market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 

The blood group typing market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The blood group typing market in the Middle East & Africa has been segmented into the Middle East and Africa.

Key players

Bio-Rad Laboratories, Inc., Grifols International, S. A., Beckman Coulter, Immucor, Inc., Ortho Clinical Diagnostics, Inc., Quotient, Ltd., Novacyt Group, Bag Healthcare GmbH, Rapid Labs, AXO Science, Agena Biosciences, Inc., Day Medical SA, and Merck KGaA are some prominent player in the market.

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/blood-group-typing-market-6410